ABSTRACT Aim: From birth to old age, males generally have poorer disease outcomes compared to females. Preterm infants display a marked gender disparity in disease outcomes, and the underlying mechanisms are not well delineated. Our aim was to review the literature on clinical outcomes between preterm infants of different genders and discuss the potential mechanisms underlying the differences observed.
INTRODUCTION
Females exhibit a survival advantage compared to males throughout the lifespan. The 'male disadvantage hypothesis' suggests that males are more sensitive to adverse environmental factors during gestation, infancy and childhood (1) . Although increased male mortality is present throughout life, this disparity is particularly evident during the newborn period and is most marked in prematurely born infants (<37 weeks' gestation) despite similar birthweight distributions. Male sex is associated with a higher risk of neurological, pulmonary, cardiovascular and infectious morbidities as well as overall mortality when compared to female infants of similar preterm gestation (2) . The differences in clinical outcomes are more evident at earlier gestations, with male neonates having poorer outcomes across weight centiles (3) . Preterm birth also entails a significant risk of chronic adverse health sequelae including sepsis, retinopathy, persistent hypotension, pulmonary hypoplasia, respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), intraventricular haemorrhage (IVH), and chronic neurodevelopmental and cognitive morbidity, among others (2, 4, 5) . Prematurity is significantly correlated to increased inflammatory consequences and comorbidities for the newborn, and it is established that males and females mount differing immune responses to infective stimuli (6) . Differences in clinical outcomes between sexes may represent a complex interaction between immunological, hormonal and genetic factors (7) . In this review, we discuss the differences in clinical outcome between male and female preterm infants, the potential mechanisms underlying these differences and their implications for future research and management.
SEX-SPECIFIC OUTCOMES IN UTERO
Sex-specific differences in outcomes may begin in genomewide differences. Genetic and epigenetic disparities between males and females are thought to influence the Abbreviations BPD, Bronchopulmonary dysplasia; E 2 , 17-b-oestradiol; ECMO, Extracorporeal membrane oxygenation; IVH, Intraventricular haemorrhage; MRI, Magnetic resonance imaging; P, Progesterone; PVL, Periventricular leukomalacia; RDS, Respiratory distress syndrome.
Key notes
Preterm male infants have poorer short-and long-term outcomes compared to females. The aetiology of these differences is not fully determined but likely involves immunological, genetic and hormonal differences. Consideration should be given to gender as a variable affecting outcome when designing experimental and clinical research in neonatology. structure and function of the placenta leading to differential susceptibility to in utero stress and contributing to disease susceptibility after delivery (8) . In preterms born at <32 weeks' gestation, male sex has been associated with increased placental lesions, potentially signifying an aberrant maternal immune response against the male (XY) interstitial trophoblast (9) . Pregnancies with a male foetus have also been associated with higher rates of complications such as pre-eclampsia (10) and higher risk of foetal distress during labour (11) . In combination, this suggests that the in utero environment differs largely between sexes, with significant implications for both the mother and foetus during pregnancy and in the perinatal period.
Approximately 55% of preterm births occur in males, and the over-representation of males in this population is exaggerated in very preterm deliveries (12) . Post-partum, female-female twins have lower early neonatal and infant mortality and decreased risk of respiratory morbidity compared to male-male twins of all gestational ages (13) . In dizygotic twin pairs of dissimilar sex, male neonates appear protected from respiratory morbidity by having a female cotwin (13) . In dichorionic twin pregnancies, the presence of a female cotwin is associated with a higher birthweight, longer duration of pregnancy and higher in utero growth rate, whereas the presence of a male cotwin is associated with increased risk of preterm delivery and prematurity-related morbidity (14) . For female neonates, the presence of a male rather than a female cotwin is associated with an increased risk of respiratory and neurological morbidity at a similar level to that observed in male twins (14) .
Male and female foetuses adapt differently to developmental stressors. Sex steroids are noted to have a profound influence on the development and progression of developmentally programmed disease states. Maternal sex steroid levels steadily rise throughout pregnancy with a dramatic increase noted during the third trimester. The abrupt and early absence of placental oestrogens and related metabolites following preterm birth has been implicated in certain pathologies including reduced skeletal mineral accretion and chronic lung disease (15). Trotter et al. randomised female infants born at <29 weeks to either placebo or postnatal 17-b-oestradiol (E 2 ) and progesterone (P) replacement with doses adjusted to maintain a plasma E 2 concentration of 2000-6000 pg/mL and plasma P concentration of 300-600 ng/mL (16) . Preterm females randomised to the treatment arm (n = 15) had a tendency towards improved bone mineral accretion and lower rates of chronic lung disease, although these did not reach statistical significance. A subsequent, larger randomised trial enrolling 83 preterm females by the same investigators failed to show any improvement in the short-term outcomes of BPD or mortality following a similar replacement regimen (17) . However, a follow-up study of these infants found a significant time-response relationship between supplementation and neurodevelopmental outcomes at five years of corrected age, with each day of treatment significantly reducing the risk of cerebral palsy and spasticity (15) . A Cochrane review examining oestrogen and progesterone supplementation in preterm infants concluded that there was insufficient evidence to recommend their incorporation into clinical practice at present (18) . There was also ongoing concern regarding the side-effect profile of hormone replacement for treated neonates, especially preterm males, as previous maternal treatment with synthetic oestrogen derivatives (diethylstilbestrol) has been associated with adverse birth outcomes (e.g. testicular and urogenital abnormalities) (19) . A detailed knowledge of the steroid environment of the foetus and newborn has important implications for a variety of peripartum medications with possible sex-specific effects.
GENDER, BRAIN INJURY AND NEURODEVELOPMENTAL OUTCOMES IN PRETERM INFANTS
Neurodevelopmental differences manifest from an early age in infancy with females having a lower incidence of developmental delay and learning difficulties in comparison with males. Male sex has consistently been identified as a risk factor for cerebral palsy in epidemiological studies (20) with males also having a higher incidence of learning disability, autism and attention-deficit/hyperactivity disorder (21) . Preterm males have a higher incidence and increased severity of brain lesions, such as IVH and periventricular leukomalacia (PVL), with follow-up data suggesting that major cranial abnormalities on neuroimaging are more common in males (5, 22) . Despite the higher incidence of such abnormalities in males, it has been suggested that extremely preterm male infants also have a higher risk of adverse neurological outcome in the absence of severe IVH or PVL (23) . Both the differences in the in utero steroid environment (24) and higher cerebral blood flow present in male infants (25) have been implicated in the higher susceptibility of male neonates to brain injury. Twin studies have shown that female neonates in malefemale twins have increased risk of IVH in comparison with female-female pairs (14) , although the mechanism of this difference remains unknown.
For preterms, male sex is also a risk factor for long-term cognitive, behavioural and neurological sequelae. Followup studies of preterm infants at high risk of perinatal hypoxia show that males have poorer clinical outcomes (26) . The EPICURE study was a large prospective observational study of preterm neonates born <26 weeks' gestation, which followed infants through childhood. Follow-up of this cohort at 30 months revealed that boys were more likely to have cerebral palsy and impaired cognitive function (27) . The Extremely Preterm Infants study in Sweden (EXPRESS) was a population-based prospective cohort study, which enrolled preterm neonates born at <27 weeks' gestation. At 30 months of age, cognitive and language outcomes were poorer in boys with delayed myelination on magnetic resonance imaging (MRI) (28) . The gender disparity in neurodevelopmental outcomes appears to be particularly marked in extreme prematurity with male sex being associated with lower cognitive, motor and language scores on Bayley-III scoring at 12 months of corrected age in infants born at <32 weeks' gestation (29) .
Over-representation of males in preterm live births may partly explain the male excess in the cerebral palsy cohort after preterm birth. However, there is strong evidence in animal models of induced intrauterine hypoxia that males are more sensitive to oxidative stress (30) . The release of catecholamines during labour is an important defence mechanism by the hypoxic foetus. Preterm females have significantly higher catecholamine levels than males (31) , which may contribute to the better outcome in females following hypoxia. Mirza et al. (32) report that mice with induced neonatal hypoxia had marked differences in outcome depending on the sex of the foetus with females having smaller brain lesions and displaying less sequelae. Male mice in this study also had an up-regulated immune response to the hypoxic episode with increased microglial activation, suggesting that differences in neurological outcomes may be affected by a sexually dimorphic innate immune response (32) . Important neurobiological differences exist between genders with respect to neuronal injury (22) . Recessive X-linked chromosome variants may contribute to this difference, and males may be more vulnerable to genetic mutation (point or copy number) than females (33) .
GENDER AND RESPIRATORY OUTCOMES IN PRETERM INFANTS Preterm males have a higher incidence of RDS, pneumothorax, early respiratory support and subsequent BPD (34).
The overall heightened mortality that exists for preterm males can be largely attributed to increased acute respiratory disorders, which is due, in part, to delayed lung maturation in the male (35) . Surfactant is produced earlier in gestation in females, contributing to the comparative respiratory disadvantage for males, and this difference in surfactant production may be mediated by positive effects of female sex hormones on surfactant production in utero (36) . The positive roles of oestrogens on surfactant production and alveologenesis have been widely described. Combined treatment of murine embryonic alveolar cell type II and central lung fibroblast cell lines with E 2 and P increased vascular endothelial growth factor mRNA and surfactant proteins, suggesting E 2 and P are intrinsically involved in lung development and postnatal respiratory function (36) . Furthermore, androgens are thought to inhibit antenatal lung development and reduce tissue levels of glucocorticoid receptor mRNA and protein in foetal rat lungs following antenatal administration (37) .
With expectant preterm delivery, antenatal steroids are administered attempting to reduce postnatal respiratory morbidity in the preterm neonate. Antenatal steroids (e.g. betamethasone) are known to have sex-specific effects on microvascular blood flow, which are thought to contribute to the male disadvantage observed in the preterm population (38) . There is also evidence that sex-specific placental responses to antenatal glucocorticoids may result in differences in oxidative stress (39) and adrenal suppression (40) in the preterm neonate, factors thought to contribute to male clinical instability and adverse outcome following preterm birth.
GENDER AND CARDIOVASCULAR OUTCOMES IN PRETERM INFANTS
Congenital heart disease is approximately twice as common in the preterm population, and the aetiology of this remains poorly understood. Former preterm infants have an unfavourable cardiac profile compared to term-born counterparts as measured by persistently abnormal neonatal echocardiography findings (41) . They also have higher blood pressure, higher fasting blood glucose and higher blood cholesterol in the preschool period (42) , with an increased risk of adult cerebrovascular disease (43) . Very low birthweight (<1.5 kg) male neonates have lower blood pressures than females on day 1 of life (44), and extremely preterm males are more likely to require treatment for hypotension within the first week of life (45) . Male sex is a risk factor for persistent pulmonary hypertension (46) . There is evidence favouring a male predominance in the requirement for extracorporeal membrane oxygenation (ECMO) therapy in the neonatal population. One large retrospective study of 8005 paediatric patients requiring ECMO noted that 62% of their neonatal patients were male (47) .
INFECTION AND INFLAMMATORY RESPONSE IN PRETERM INFANTS BY GENDER
Important differences in the immune response between male and female preterm neonates have been noted (7). In both adult and neonatal populations, experimental, clinical and epidemiological studies indicate improved prognosis for females after a septic challenge (6) . Preterm neonates are at high risk of acquiring severe bacterial infection compared to term neonates, and the altered immune response of preterms persists over time, with older children who were born before term having increased rates of chronic immune dysfunction and dysregulation (48) . Placental cultures are more likely to be positive in males, and placental histology reveals a higher infiltration of the decidua by lymphoplasmacytic cells in males, suggesting a maternal immune reaction to male foetal tissue (9) . Results from animal models indicate sexually disparate responses following infective stimuli, and elements of this immune dichotomy may be due, in part, to the influence of sex steroid hormones in the neonatal period (49). Roy et al. (50) report that preterm and low birthweight infants who were blood culture-positive in the neonatal period were more likely to be male. Male sex has also been identified as a significant risk factor for the development of fungaemia in preterm neonates in a tertiary neonatal intensive care setting (51) .
Preterm infants are sex-specific in their immune response to the prostaglandin inhibitor and the anti-inflammatory drug indomethacin (22) . The Trial of Indomethacin Prophylaxis in Preterms (TIPP) study was a large randomised controlled trial of indomethacin prophylaxis in the prevention of IVH in preterm infants weighing between 500 and 999 g (52) . Three doses of indomethacin were administered at 24-hour intervals following randomisation, and initial results suggested that although it reduced the incidence of IVH, there was no impact on long-term neurodisability (52) . Following suggestion of a differential effect of indomethacin between genders, results of the TIPP study were re-analysed and found that for the composite outcome of death and survival with disability, treated males had improved outcomes, suggesting a differential sex response (53) . In addition, indomethacin administration was significantly associated with higher verbal scores at three to eight years of age (54), a significant reduction in IVH in males only (54) , and may decrease functional MRI abnormalities in key areas of the brain responsible for subsequent language development in treated male infants (55) .
Data from animal and human studies suggest the male vulnerability to inflammatory stimuli is present both antenatally and postnatally (22) . Preterm males, more susceptible to brain injury in the perinatal period, seem to be significantly protected by prostaglandin inhibiting and antiinflammatory agents, underscoring the importance of stratifying results of preclinical and clinical studies on neuroprotection by gender (22) . Sex differences in immune function between males and females exist throughout life with innate and adaptive immunity differences beginning in utero likely due to a combination of hormonal and genetic factors (56) .
TREATMENT
In addition to the differential neuroprotective effect noted with indomethacin (53-55), other therapeutic agents have been noted to affect outcomes differently depending on sex. Animal models of neonatal encephalopathy have suggested that allopurinol may have a greater role in neuroprotection in females than males (57) . Post hoc analysis of a randomised controlled trial investigating maternal allopurinol administration (n = 222) and its effect on biomarkers of brain injury also support a differential sex effect, with treated female neonates having lower levels of neuroketal in cord blood than untreated female infants, an effect that was not present among males (58) . Due to the frequency with which preterms are exposed to antenatal glucocorticoids, sex may represent an important consideration in the dosing and timing of these medications (59) .
FUTURE RESEARCH POSSIBILITIES
At present, the continued disparity in health outcomes between preterm males and females remains incompletely understood and represents an important area for future clinical and scientific investigation. The reporting of outcomes in clinical studies by gender should be a key area of focus. There is also a need to consider the potential effect of gender when designing trials on therapeutic interventions to which male and female infants may respond differently. The suggested sex-specific effects of antenatal steroids (59) raise important questions about the need for altered dosing of this and other medications depending on gender. Further experimental work is needed to investigate the effect of antenatal glucocorticoids and oestrogen-like medications on preterm health in order to improve our understanding of perinatal diseases.
CONCLUSION
The aetiology of sex-specific differences in disease among preterms remains relatively undetermined and is likely multifactorial, with genetic, immunological and hormonal influences playing key roles and representing important areas for future research. Within the neonatal population, there is need for further recognition and investigation of the potential for sexually disparate responses to both novel and established treatments. Gender as a variable and risk factor for disease incidence and progression in preterms is not appreciated in large-scale randomised controlled trials involving preterm cohorts. However, comparative analysis of gender in preterm disease may elucidate further differences in clinical outcome. Recognition of such differences and their consideration when designing experimental and clinical research are likely to yield valuable results and allow researchers and clinicians to optimise care for both sexes. 
